TRACON PHARMACEUTICALS INC's ticker is TCON and the CUSIP is 89237H209. A total of 37 filers reported holding TRACON PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $492,265 | -38.8% | 2,765,530 | 0.0% | 0.06% | -53.9% |
| Q2 2023 | $804,769 | -84.6% | 2,765,530 | 0.0% | 0.13% | -89.2% |
| Q1 2023 | $5,226,851 | +26.8% | 2,765,530 | 0.0% | 1.19% | +19.3% |
| Q4 2022 | $4,120,639 | -10.8% | 2,765,530 | 0.0% | 0.99% | +8.0% |
| Q3 2022 | $4,618,000 | -17.2% | 2,765,530 | -0.8% | 0.92% | -9.5% |
| Q2 2022 | $5,577,000 | -25.4% | 2,788,853 | -1.9% | 1.02% | +3.5% |
| Q1 2022 | $7,477,000 | +0.3% | 2,843,232 | +5.7% | 0.98% | -11.4% |
| Q4 2021 | $7,454,000 | -28.4% | 2,691,110 | 0.0% | 1.11% | +51.4% |
| Q3 2021 | $10,415,000 | -40.9% | 2,691,110 | -0.9% | 0.73% | -48.6% |
| Q2 2021 | $17,631,000 | -21.1% | 2,716,840 | 0.0% | 1.42% | +89.2% |
| Q1 2021 | $22,360,000 | -29.7% | 2,716,840 | 0.0% | 0.75% | -46.3% |
| Q4 2020 | $31,787,000 | +184.3% | 2,716,840 | +25.6% | 1.40% | +73.3% |
| Q3 2020 | $11,180,000 | – | 2,162,549 | – | 0.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 4,764,508 | $9,004,920 | 2.70% |
| Ikarian Capital, LLC | 2,765,530 | $5,226,851 | 1.19% |
| JOHNSON & JOHNSON | 84,003 | $158,766 | 0.05% |
| X-Square Capital, LLC | 17,743 | $34 | 0.02% |
| BOOTHBAY FUND MANAGEMENT, LLC | 258,844 | $489,215 | 0.01% |
| LINDEN ADVISORS LP | 454,916 | $859,791 | 0.01% |
| HoyleCohen, LLC | 13,000 | $24,570 | 0.00% |
| MGO ONE SEVEN LLC | 11,780 | $22,264 | 0.00% |
| Bank of New York Mellon Corp | 66,606 | $125,885 | 0.00% |
| Citadel Advisors | 24,700 | $46,683 | 0.00% |